P2Y12 receptor antagonists, including Ticagrelor, are routinely used in patients with acute coronary syndromes. Inhibition of the P2Y12 receptor somehow triggers cardioprotective signaling via a platelet-dependent mechanism. Recently, we observed that the NLRP3 inhibitor, INF4E, significantly reduce infarct size in isolated hearts. Here we hypothesized that INF4E can add its protection to that from the Ticagrelor with the involvement of Reperfusion Injury Salvage Kinase (RISK)pathway.
Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury?
Elisa Zicola;Saveria Femminò;Fausto Chiazza;Debora Collotta;Massimo Collino;Manuela Aragno;Massimo Bertinaria;Pasquale Pagliaro;Claudia Penna
2020-01-01
Abstract
P2Y12 receptor antagonists, including Ticagrelor, are routinely used in patients with acute coronary syndromes. Inhibition of the P2Y12 receptor somehow triggers cardioprotective signaling via a platelet-dependent mechanism. Recently, we observed that the NLRP3 inhibitor, INF4E, significantly reduce infarct size in isolated hearts. Here we hypothesized that INF4E can add its protection to that from the Ticagrelor with the involvement of Reperfusion Injury Salvage Kinase (RISK)pathway.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Vascular pharmacology 2020, 132, 106752.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
51.05 kB
Formato
Adobe PDF
|
51.05 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
